Giorgia Gerolimetto

Giorgia Gerolimetto

Auto-generated profile, based on publicly available information

Giorgia Gerolimetto

Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, Würzburg, Germany, 97074

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2026 in RNA
Verified
Journal Article
Open access
PDF file
JVJörg Vogel
Jörg Vogel
CKCharlotte Kamm
Charlotte Kamm
GGGiorgia Gerolimetto
Giorgia Gerolimetto
PMPranjal Meel
Pranjal Meel
ATAlexandre Trubert
Alexandre Trubert
CFChristian Fröschel
Christian Fröschel
RNAmed - Future Leaders in RNA-based Medicine is a unique graduate training program in the area of RNA-based medicine. Financed by the Free State of Bavaria, Germany, it is jointly run by several universities and research institutes from Würzburg, Regensburg and Munich. It aspires to equip doctoral students with a comprehensive idea of RNA therapeutics, spanning fundamental biology, translational research, clinical application, regulation, ethics, and societal implications. This integrative approach is meant to cultivate exceptional qualifications for careers across academia, industry, and policy. The RNAmed program held its 2025 annual retreat on San Servolo (Venice, Italy), with a total of 40 doctoral researchers, principal investigators (PIs), and invited guests from academia and pharmaceutical industry attending. The three-day program combined keynotes, student presentations, flash talks, a career panel and topic-table discussions of advances and challenges across RNA therapeutics to catalyze exchange and collaboration. Presentations highlighted emerging directions for antisense strategies, circular RNAs, delivery technologies, and AI-enabled molecular design, reflecting the program’s cross-disciplinary nature. Discussions emphasized shared priorities such as clear experimental standards, robust delivery solutions, and stronger academia–industry ties to accelerate safe, effective RNA medicines. Updates on RNAmed’s growth and extended funding underscored its mission to develop talent through integrated scientific and professional training. Overall, the retreat strengthened a network of early-career scientists and mentors committed to advancing RNA-based modalities from concept to clinic.

9 August 2026 in ChemRxiv
Verified
Preprint
Open access
GGGiorgia Gerolimetto
Giorgia Gerolimetto
JCJustyna A. Czaplewska
Justyna A. Czaplewska
JKJosef Kehrein
Josef Kehrein
IAIlayda Ates
Ilayda Ates
ESEmma Steffens
Emma Steffens
LMLorenz Meinel
Lorenz Meinel
Poly(ethylene glycol) (PEG) is the standard stealth polymer to functionalize lipid nanoparticle (LNP) surfaces, requiring conjugation to a lipid tail for anchoring in the LNP’s shell. We eliminate the need for lipid conjugates by introducing a new polymer-only design principle using function-encoded statistical polymers. For that, we synthesized statistical amphiphilic copolymers in which hydrophobic units are followed by hydrophilic units, with the intention that the hydrophobic units of the polymer anchor to the LNP surface, and its hydrophilic parts stealth the particle surface. We screened the formulation space using a 42-member poly(2-oxazoline) library, yielding design rules for successful LNP formulations. Cryogenic transmission electron microscopy confirmed the intact LNP structure, and biological activity was assessed in multiple human cell types differentiated from inducible pluripotent stem cells. Intravenously administered barcoded LNPs formulated with function-encoded statistical polymers compared to the equivalent PEG-lipid LNPs showed 2.5- and 5-fold higher amounts in mice and lower bloodstream levels, leading to significantly higher accumulation in the spleen and liver. Rather than assembling LNP interfaces from multiple molecular components, this work establishes that orthogonal interfacial functions can be encoded directly into the architecture of a single statistical polymer, providing a general molecular design principle for programmable nanomedicine interfaces.

17 November 2026 in ChemRxiv
Verified
Preprint
Open access
FAFranziska Adermann
Franziska Adermann
GGGiorgia Gerolimetto
Giorgia Gerolimetto
CHCaroline T. Holick
Caroline T. Holick
IAIlayda Ates
Ilayda Ates
ESEmma Steffens
Emma Steffens
LMLorenz Meinel
Lorenz Meinel
The interface between lipid nanoparticles (LNPs) and their biological environment represents a key determinant of biodistribution. Here, we investigated poly(2-ethyl-2oxazoline) (PEtOx)-lipids as an adaptable component of this interface and determined how polymer chain length affects LNP formulation as well as biological behavior. Rather than comparing different polymers with a single nominal formulation composition, we first mapped the pharmaceutical design space of four PEtOx-lipids containing average chain lengths of 20, 34, 49, or 71 repeating units and identified formulation conditions that supported acceptable LNP formation. This shared design space subsequently enabled the comparison of chain-length-dependent effects under pharmaceutically viable conditions. Increasing PEtOx chain length decreased the apparent hydrophobicity of the PEtOx-lipids and was associated with progressively smaller LNP diameters, lower mRNA encapsulation efficiencies, and a narrower formulation space in which predefined criteria for size, polydispersity, and mRNA loading were met concomitantly. Optimized PEtOx-LNPs mediated mRNA expression across multiple primary and human induced pluripotent stem cell-derived cell types with limited effects on cell viability. Pooled in vivo DNA barcoding of the PEtOx20-, PEtOx34-, and PEtOx49-LNPs revealed chain-length-dependent differences in relative organ barcode distribution, with shorter chains shifting relative distribution toward spleen and pancreas and away from bone marrow and liver. Together, these findings establish PEtOx chain length as an independent LNP design parameter and demonstrate a formulation-space-based strategy for comparing polymeric excipients without relying on a single predefined formulation composition.